Miller is presenting 3 sessions at the 2023 Fall Clinical Dermatology Conference for PAs and NPs.
An expert in the management of skin conditions provides an overview of a 20-year-old male diagnosed with atopic dermatitis, discussing key insights from a round table discussion. The conversation focused on effective management strategies, best practices for prior authorization approvals, and the significance of treatment vehicles.
John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.
Social media is fraught with misinformation. Pharmacists play a key role in breaking through the fallacies with facts and education on skin care.
What we know about monkeypox in pregnancy, including treatment recommendations, vaccination, and postpartum care.
Julia Zimmermann, PD, PHD's innovative cold plasma technology for acne treatment, developed through extensive research, promises effective results for clearer skin.
Researchers from the University of Michigan and Almirall found that the profibrotic fibroblast response in HS can be modulated through inhibition of the Hippo pathway.
TJ Chao, MPAS, PA-C, discusses tips for educating patients and raising awareness about prurigo nodularis, focusing on the importance of informing patients about the role of systemic treatments and empowering them to make informed decisions about their care.
Tirbanibulin (Klisyri, Almirall) has been approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of actinic keratosis on the face or scalp.
In this CME article, learn more about the interdisciplinary field of psychodermatology and the collaborative health care team necessary for care.
There are barriers to telehealth adoption that physicians must overcome to realize the technology’s promise.
More research is needed to understand the pathogenesis underlying this association.
Understanding the difference in biology and clinical presentations of cutaneous conditions in different skin types is critical for health care professionals to treat a diverse population.
Researchers have explored whether the adverse effects of tazarotene are exacerbated during the colder winter months and whether there is variation in treatment efficacy and tolerability between cold vs warm seasons.
The panelist discusses how the therapeutic options for atopic dermatitis have expanded significantly with the emergence of targeted biologics, oral agents, and refined topical treatments, transforming the management approach for patients across the disease spectrum.
As newly appointed Executive Director of the Foundation, Becky Kamowitz is combining public education with clinical needs in the fight against skin cancer.
Scott Batty, MD, and Chris VanDeusen, PhD, provided insights on AX-158's phase 2a results, presented at the SID Annual Meeting.
In a recent Dermatology Times DermView video series, “Advancing Care in Pediatric Plaque Psoriasis: Emerging Treatments and Management Strategies," Karan Lal, DO, and Helen Shin, MD, discuss pediatric psoriasis and its prevalence.
Stephen Tyring, MD, PhD, MBA, covers the burden of antimicrobial resistance and the need for alternative treatments.
In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.
At the AAD Annual Meeting, Roy G. Geronemus, MD, emphasized the importance of early interventions for port wine stains.
Payers must make public the individual amounts their health plans pay providers across all types of services and locations, including hospitals, doctors’ offices, imaging centers, outpatient surgery centers and urgent care clinics.
In recent years, there has been a noticeable rise in diagnoses of sexually transmitted infections, often which present with skin findings.
Last week, the US Food and Drug Administration approved biosimilar ustekinumab-aekn (Selarsdi; Alvotech and Teva) for psoriasis and PsA.
Brandon Beal, MD shared his experience, which technology solutions work best, and resources available to dermatology practices.